Does tacrolimus cause peripheral neuropathy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Does Tacrolimus Cause Neuropathy?

Yes, tacrolimus definitively causes peripheral neuropathy as a recognized neurotoxic adverse effect, though it occurs less commonly than other side effects like nephrotoxicity or new-onset diabetes.

Evidence from FDA Drug Label

The FDA-approved drug label for tacrolimus explicitly warns about neurotoxicity 1. Tacrolimus may cause a spectrum of neurotoxicities including tremors, paresthesias, headache, mental status changes, and changes in motor and sensory functions 1. The label specifically states that symptoms may be associated with tacrolimus whole blood trough concentrations at or above the recommended range, and recommends monitoring for neurologic symptoms with consideration of dosage reduction or discontinuation if neurotoxicity occurs 1.

Clinical Context and Characteristics

Tacrolimus-induced peripheral neuropathy has been documented across multiple transplant types:

  • In psoriasis treatment guidelines, tacrolimus side effects are noted to include "neurotoxicity (tremors, paresthesias, and insomnia)" 2
  • In transplant monitoring guidelines, tacrolimus administration has been associated with neurotoxicity, with adverse events including "numbness, tingling" 3
  • In autoimmune hepatitis guidelines, tacrolimus use notes that "serum urea and creatinine levels were raised within a year of treatment" in the context of neurologic monitoring 4

Case Report Evidence

Multiple case reports confirm tacrolimus-induced neuropathy:

  • A 2024 literature review identified 28 case reports of tacrolimus-induced neurotoxicity, with severity ranging from mild symptoms to conditions like chronic inflammatory demyelinating polyradiculoneuropathy 5
  • A 2022 case described unilateral common peroneal nerve palsy (foot drop) occurring even with below therapeutic tacrolimus levels in a heart transplant patient, suggesting idiosyncratic reactions can occur 6
  • A 2013 case reported bilateral foot drop and encephalopathy in a renal transplant recipient who had inadvertently overdosed on tacrolimus 7
  • A 2010 case documented progressive symmetric demyelinating sensorimotor polyneuropathy in distal lower limb muscles after heart transplantation, which suddenly reverted after tacrolimus was stopped 8
  • A 2008 case described pure motor axonal polyneuropathy of the lower limbs occurring just 9 days post-transplant 9

Incidence and Risk Factors

A 2023 prospective study of 77 renal transplant recipients found that peripheral neuropathy was among the adverse effects observed with tacrolimus use 10. The study also noted that higher tacrolimus trough levels were associated with increased adverse effects.

Clinical Management Algorithm

When peripheral neuropathy is suspected with tacrolimus:

  1. Confirm the diagnosis - Look for symmetric, distal sensory or motor symptoms (numbness, tingling, weakness, foot drop)
  2. Check tacrolimus trough levels - Neurotoxicity can occur even at therapeutic or subtherapeutic levels 6, though higher levels increase risk
  3. Rule out other causes - Exclude infection, metabolic causes, and disease-related neuropathy
  4. Consider dose reduction first - If levels are elevated or at high-normal range 1
  5. Switch immunosuppression if symptoms persist or worsen - Change to cyclosporine or alternative agent 6, 7, 8
  6. Monitor for improvement - Recovery typically occurs over weeks to months after tacrolimus discontinuation 8

Important Caveats

  • Bortezomib caution: In patients with Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma, bortezomib-based regimens must be avoided in patients with disease-related peripheral neuropathy 11, though this relates to bortezomib, not tacrolimus
  • Timing: Neuropathy can develop early (within days) 9 or later in the treatment course
  • Reversibility: Most cases show improvement or complete resolution after stopping tacrolimus 8, though recovery may take months 7
  • Idiosyncratic reactions: Some patients develop neuropathy even at low or therapeutic levels 6, making it unpredictable

The prompt recognition of tacrolimus as the causative agent and substitution with a different immunosuppressant may prevent permanent neurological damage 7.

References

Research

Adverse Effects of Tacrolimus and Its Associated Risk Factors in Renal Transplant Recipients.

Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation, 2023

Guideline

waldenström's macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2013.

Journal of the National Comprehensive Cancer Network : JNCCN, 2012

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.